Actavis Completes Sales Reorganization, Pipeline Rationalization
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.
You may also be interested in...
Actavis Puts Greater Emphasis On Branded Rx By Taking Allergan Name
The growing spec pharma has seen a 300% increase in its branded portfolio revenues since the acquisition of Forest and Warner Chilcott and is honoring the new direction by taking on the name of its most recent acquisition.
Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.